0W4N Stock Overview A biotechnology company, develops biosimilar drugs in Germany and Switzerland. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Formycon Historical stock prices Current Share Price €54.80 52 Week High €64.30 52 Week Low €37.85 Beta 0.81 1 Month Change -8.67% 3 Month Change 13.34% 1 Year Change 7.45% 3 Year Change 21.43% 5 Year Change 95.71% Change since IPO 65.56%
Recent News & Updates
New minor risk - Share price stability Jan 21
Formycon Receives EU Approval for FYB203 (Aflibercept), A Biosimilar to Eylea, Under the Brand Names Ahzantive and Baiama Jan 21
Formycon AG and Fresenius Kabi Announce MHRA Approval for FYB202/Otulfi (Ustekinumab), Biosimilar to Stelara Jan 16
Investor sentiment improves as stock rises 15% Jan 07
Now 24% overvalued after recent price rise Jan 02 Formycon AG to Report Fiscal Year 2024 Results on Mar 27, 2025 See more updates
New minor risk - Share price stability Jan 21
Formycon Receives EU Approval for FYB203 (Aflibercept), A Biosimilar to Eylea, Under the Brand Names Ahzantive and Baiama Jan 21
Formycon AG and Fresenius Kabi Announce MHRA Approval for FYB202/Otulfi (Ustekinumab), Biosimilar to Stelara Jan 16
Investor sentiment improves as stock rises 15% Jan 07
Now 24% overvalued after recent price rise Jan 02 Formycon AG to Report Fiscal Year 2024 Results on Mar 27, 2025
Formycon AG Appoints Colin Bond as Director Nov 15
Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz) Oct 01
First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023) Aug 18
Formycon AG to Report First Half, 2024 Results on Aug 13, 2024 Aug 06
Now 24% undervalued Aug 03
Investor sentiment improves as stock rises 16% Jun 26
Investor sentiment improves as stock rises 16% Jun 06
New minor risk - Share price stability Jun 04
Formycon AG to Report Q1, 2024 Results on May 08, 2024 May 03
Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022) Apr 25
Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024 Apr 13
New minor risk - Shareholder dilution Apr 01 Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million. Jan 30
First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022) Sep 08
Formycon AG to Report First Half, 2023 Results on Aug 30, 2023 Aug 24
Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda) Jun 29
Investor sentiment improves as stock rises 16% May 18
Full year 2022 earnings released: EPS: €2.62 (vs €1.22 loss in FY 2021) Apr 30 Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million. Feb 03
First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021) Nov 01
Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab) Sep 20
Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features) Aug 29
Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis Aug 27
Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study Aug 16
Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2 Aug 04
Formycon AG Announces Supervisory Board and Executive Changes Jul 02
Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA Jun 25
Full year 2021 earnings released: €1.22 loss per share (vs €0.54 loss in FY 2020) May 22 Formycon AG Announces Changes to Its Executive Board
Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency May 19
First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020) Sep 24
Formycon AG Provides Revenue Guidance for the Year 2021 Sep 21
Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration Aug 08
Formycon AG Provides Sales Guidance for the Fiscal Year 2021 Jun 30
Full year 2020 earnings released May 19
Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy Apr 27
Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities Feb 24
Formycon AG, Annual General Meeting, Sep 27, 2021 Feb 18
Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium Jan 13
Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab) Nov 09
Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted Nov 08
Formycon AG to Report Q1, 2020 Results on Jun 22, 2020 Jul 17 Shareholder Returns 0W4N GB Biotechs GB Market 7D 1.3% -3.2% 1.0% 1Y 7.5% -19.7% 12.1%
See full shareholder returns
Return vs Industry: 0W4N exceeded the UK Biotechs industry which returned -19.5% over the past year.
Return vs Market: 0W4N underperformed the UK Market which returned 10.2% over the past year.
Price Volatility Is 0W4N's price volatile compared to industry and market? 0W4N volatility 0W4N Average Weekly Movement 7.1% Biotechs Industry Average Movement 8.4% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: 0W4N has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0W4N's weekly volatility (7%) has been stable over the past year.
About the Company Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn’s disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials.
Show more Formycon AG Fundamentals Summary How do Formycon's earnings and revenue compare to its market cap? 0W4N fundamental statistics Market cap €965.83m Earnings (TTM ) €63.90m Revenue (TTM ) €60.80m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0W4N income statement (TTM ) Revenue €60.80m Cost of Revenue €53.22m Gross Profit €7.58m Other Expenses -€56.32m Earnings €63.90m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 27, 2025
Earnings per share (EPS) 3.62 Gross Margin 12.46% Net Profit Margin 105.09% Debt/Equity Ratio 0%
How did 0W4N perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/06 14:02 End of Day Share Price 2025/02/06 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Formycon AG is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gerhard Orgonas Berenberg Benjamin Thielmann Berenberg Simon Scholes First Berlin Equity Research GmbH
Show 12 more analysts 
